跳至主要内容
临床试验/NCT02139410
NCT02139410已完成不适用

Insulin Like Growth Factor 1 and Risks of Sarcopenia and Mortality in Patients With Cognitive Impairment

University of Roma La Sapienza2 个研究点 分布在 1 个国家目标入组 589 人开始时间: 2008年6月最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
589
试验地点
2
主要终点
IGF-1 reduction in patients with sarcopenia

研究概览

简要总结

Insulin-like growth factor 1 (IGF)-1 is an important neuromyotrophic hormone. Disregulation of this hormone has been reported to influence the genesis of cognitive impairment and dementia in the elderly patients. We analyzed the possible link between IGF-1 and risk of Sarcopenia and Mortality in a cohort of elder patients with cognitive impairment.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

年龄范围
65 Years 至 90 Years(Older Adult)
性别
All
接受健康志愿者

入选标准

  • Diagnosis of cognitive impairment (MMSE < 24)
  • Age > 65 ys

排除标准

  • Diagnosis of pancreatic disorders
  • Diagnosis of acromegaly
  • Diagnosis of GH-related disorders
  • Recent bone fractures or immobility before the enrollment (3 months)

结局指标

主要结局

IGF-1 reduction in patients with sarcopenia

时间窗: baseline, 24 months, 48 months

IGF-1 reduction could be linked to sarcopenia in patients with cognitive impairment

次要结局

  • IGF-1 reduction and mortality in patients with cognitive impairment(baseline, 24 months, 48 months)

研究者

发起方
University of Roma La Sapienza
申办方类型
Other
责任方
Principal Investigator
主要研究者

Vincenzo Gianturco

MD

University of Roma La Sapienza

研究点 (2)

Loading locations...

相似试验